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Abstract 
There is a recognised potential risk of transmission of blood-borne viruses (BBVs) from infected 
healthcare workers to patients during exposure prone procedures (EPPs). The restrictions placed on 
performance of EPPs by infected clinicians in the UK have had a particularly significant impact on 
dentists, because of the exposure-prone nature of most dental procedures and the difficulties in 
identifying alternative career pathways in the profession that do not involve EPPs. More recently, 
the significant positive impact of antiviral drugs on viral load together with a re-categorisation of 
EPPs in dentistry have resulted in evolution of the guidance with a consequent significant 
improvement to the career prospects of dentists infected with BBVs. This paper provides an update 
for practitioners on the progress that has been made and outlines the current position with respect 
to practice restrictions. 
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Background 
In 2006, David Croser 1 wrote an opinion piece for the British Dental Journal entitled ‘Written off’, in 
which he described the plight of UK dentists infected with human immunodeficiency virus (HIV) and 
who, as a result, had to cease practising dentistry in the United Kingdom.  The problems faced by 
dental practitioners infected with blood-borne viruses (BBVs) were particularly acute, because 
virtually all routine clinical dental procedures were classified as exposure-prone procedures (EPPs) 
according to the Department of Health definition: ‘Those invasive procedures where there is a risk 
that injury to the worker may result in the exposure of the patient’s open tissues to the blood of the 
worker. These include procedures where the worker’s gloved hand may be in contact with sharp 
instruments, needle tips or sharp tissues (eg spicules of bone or teeth) inside a patient’s open body 
cavity, wound or confined anatomical space, where the hand or fingertips may not be completely 
visible at all times’. 2 Clearly, there are very limited career options for dentists who are unable to 
perform EPPs.  This original correspondence spawned a succession of letters and comments over 
several years in the British Dental Journal in support of changes to the guidance. 3-22 
Since David Croser’s paper in 20061 there have been a number of incremental changes to guidance 
which significantly improve the outlook for BBV- infected healthcare workers (HCWs), including 
dentists, whose work involves EPPs. In particular the outcome of the work of the UK Department of 
Health Tripartite Working Group, which included members from the Advisory Group on Hepatitis 
(AGH), the Expert Advisory Group on AIDS (EAGA), the UK Advisory Panel for Healthcare Workers 
infected with Blood-borne Viruses (UKAP), the Department of Health (DH), the National AIDS Trust 
(NAT) and other outside experts provided a persuasive case for amendment of the guidance on HIV 
infected HCWs. The ensuing change, which now permits HIV-infected HCWs to perform EPPs under 
specific conditions, represented a major breakthrough when it was launched in January 2014.23  
It is important to recognise that whilst much of the debate in the British Dental Journal has focused 
on dentists infected with HIV, very similar problems were faced by clinicians infected with hepatitis B 
virus (HBV) and hepatitis C virus (HCV). Significant advances have also been made in respect of 
opportunities to return to work for those infected with these two viruses, but have been less well 
publicised. As for HIV, many of the changes have been made possible because of major advances in 
antiviral drug discovery and the evidence base surrounding the efficacy of these drugs in reducing 
the risk of transmission.  Furthermore, recent review of the classification of EPPs in dentistry by 
UKAP has resulted in significant amendments which are likely to have a potentially positive impact 
for dentists infected with BBVs. 
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Recognition should also be given to the response of the dental profession in engaging with the need 
for universal high standards of infection control when treating patients.24 Furthermore, the value of 
participating in a regular inspection of all dental surgeries by an independent third party mandated 
by law has had a significant impact through the work of the Care Quality Commission 
(http://www.cqc.org.uk/content/dentists) and, in Scotland, the Combined Practice Inspection  
(http://www.sdpbrn.org.uk/completed-projects/combined-practice-inspection/). 
This paper aims to provide a summary of the background to the changes that have been introduced 
and ensure the reader is familiar with the current UK position for the management of BBV-infected 
HCWs. 
 
Healthcare worker to patient transmissions 
Patient safety is the pre-eminent issue in all policy making in this area and it must be acknowledged 
that there have been verified transmissions of HIV, HBV and HCV to patients from infected HCWs, as 
referenced below. The risk of transmission depends not only on the procedure type and relative 
infectivity of the virus itself (HBV>HCV>HIV) but also on the HCW’s viral load, which partly explains 
the complexity of the guidance. Our knowledge of the level of risk posed by HCWs to patients in this 
wide range of possible infective states has taken many years to accumulate. Much of that knowledge 
is based on epidemiological and molecular virological studies of identified transmissions, an evolving 
process which continues and a summary of which now follows. 
HIV 
Since the early 1990s, dentistry has carried the burden of the first reported transmission of HIV from 
an infected HCW to a patient. The highly publicised and widely reported ‘Florida Dentist’ case,25, 26 in 
which six patients of David Acer were infected with HIV, caused significant public alarm27, 28 as well 
as concern among all those involved in healthcare delivery. Extensive molecular epidemiological 
investigations were undertaken29, 30 which showed that the dentist and the six patients were 
infected with very closely related strains of HIV, but the mechanism of the transmissions has never 
been identified. This incident was closely followed by two separate look back exercises relating to 
HIV-infected dentists in the USA,31, 32 neither of which identified any transmissions. 
Since then, there have been only three further reported transmissions from HIV-infected HCWs. 
These incidents relate to transmission from an orthopaedic surgeon,33, 34 a nurse35 and an 
obstetrician,36 in each case to a single patient. 
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In the final report of the DH Tripartite Working Group in 2011, the risk of transmission of HIV from 
an infected HCW to a patient during a category 1 or 2 EPP (which includes all procedures in general 
dental practice) was described as negligible.37 The risk estimate for an HIV-infected HCW on 
combination antiretroviral therapy (cART) transmitting HIV to a patient during a category 3 EPP 
ranged from 1 in 33,000 to 1 in 833,000.37  
HBV 
Hepatitis B virus is the most infectious of the BBVs. A significant exposure of a non-immune HCW to 
a significant sharps injury from an HBeAg positive patient carries a 1 in 3 chance of transmission. Not 
surprisingly, therefore, the risk to patients from infected HCWs is correspondingly high. The first 
indications of a possible risk to patients emerged in 197438-40 with reports of acute hepatitis in 
patients of two chronically infected dentists. The evidence for risks from infected dental personnel 
became more concrete over the next few years.41, 42   An interesting review in 1986, which examined 
the potential for HBV transmission to patients from infected HCWs, identified dentistry as an 
especially high risk area, noting the common themes of HBeAg positivity in source HCWs and the 
impact of glove wearing.43 The preventive role of operating gloves was demonstrated graphically in 
one study of a dentist who infected 55 patients over a period of approximately  three years when he 
operated un-gloved but did not infect any of 8000 subsequent patients once he commenced routine 
glove wearing.44 Whilst procedures such as glove use have had a major impact in reducing risk, it was 
clear that transmissions could still occur even when infection control procedures were followed , as 
exemplified by transmissions from a thoracic surgeon to 19 patients reported in 1996.45 This case, 
and others, of transmissions from HBeAg positive HCWs resulted in guidance which prevented such 
individuals from undertaking EPPs in the UK. 46  
However, it subsequently became evident that HBeAg negative HCWs could also transmit HBV to 
patients.47  These HCWs were shown to have high HBV DNA levels and consequently a further 
tightening of regulation requiring measurement of viral load for those HCWs who were HBsAg 
positive but HBeAg negative was introduced. 48 
Successful implementation and the efficacy of the policies for HBV infected HCWs has resulted in 
there being no detected transmission of HBV from HCWs to patients since the policy changed in 
2000. 
HCV 
There have been well characterised transmissions of HCV to patients during healthcare procedures.49 
Most commonly these appear to have been related to unsafe use of injecting equipment and other 
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infection control breaches,50, 51 but there have also been transmissions from infected HCWs to 
patients, typically cardiothoracic surgeons and obstetrician-gynaecologists.49, 52 To date, there have 
been no reported transmissions from infected dental professionals to patients.  
There remain some uncertainties about routes of transmission of HCV in the healthcare setting, 
which explain the continuing EPP restrictions in the UK of HCV RNA-positive HCWs.  
 
The impact of advances in anti-viral drugs on management of the infected health care worker 
Dramatic advances in the development of antiviral drugs have been made since the approval in 1963 
of the first antiviral agent, idoxuridine, for use in humans. At the time of writing, 90 antiviral drugs 
have been approved for human use and there is an excellent recent review of the progress made 
over the past 50 years for the interested reader.53 It is fortunate that among the group of nine viral 
infections of humans for which effective antivirals have been developed, HBV, HCV and HIV are 
included. A summary of the current position for each virus follows below.   
HIV 
The advances that have been made in both development and use of antiretroviral drugs in recent 
years have been highly significant.54 These drugs have had a positive impact on both the treatment 
of established infection and in prevention, although it is important to recognise that none are 
curative.  
The clinical efficacy of combination antiretroviral chemotherapy became evident in the mid-1990’s, 
resulting in the first set of published treatment guidelines in 1996.55 There are now multiple 
antiretroviral drugs available, with a variety of modes of action, rendering the management of HIV 
disease a highly specialised area of medicine. The complexities of drug types and clinical situations 
have resulted in a need for clear recommendations on how and when to use antiretroviral drugs, 
with a pace of change which is so fast that very regular updating is required. For example, the 
recommendations of the International Antiviral Society-USA Panel published in 201656 replaced 
those published as recently as 2014,57 whilst the equivalent documents from the British HIV 
Association published in 2015 required an interim update for 2016 (http://www.bhiva.org).  
Discovery of one of the newer classes of antiretroviral drugs known as integrase strand transfer 
inhibitor agents (InSTIs) has been a major step forward and regimens based on this class of drug are 
currently viewed as optimal for initial therapy.56 These drugs are highly effective at virological 
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suppression in comparison with other classes of antiretroviral drugs58, 59 and are extremely well 
tolerated.60 
In addition to the new drugs themselves, clinical trials have shown the benefits of beginning 
antiretroviral therapy early after infection,56 benefiting not only the individual patients but also 
making them significantly less infectious to their partners,61 thereby integrating treatment and 
prevention.  
These drugs have highly significant relevance to HIV-infected HCWs who wish to undertake EPPs, by 
virtue of their ability to reduce the viral load to a level which poses no risk of transmission to 
patients,23 as described below. They are also, of course, the basis of HIV post-exposure prophylaxis 
following inoculation injuries.62  
HBV 
The antiviral drug treatment of patients with chronic hepatitis B infection has improved significantly 
in recent years, although a cure remains elusive.63 There are currently seven antiviral drugs that have 
approval for the treatment of chronic hepatitis B.64 These include immunomodulatory agents 
(interferon-alpha and pegylated interferon), oral nucleoside analogues (lamivudine, telbivudine and 
entecavir) and nucleotide analogues (adefovir and tenofovir). The nucleoside and nucleotide 
analogues are now the mainstay of treatment for chronic hepatitis B. Their efficacy has been 
demonstrated in normalising ALT, HBV DNA suppression, HBeAg seroconversion, reducing 
progression of liver fibrosis and reducing the rate of decompensation.64 These drugs, which are very 
effective at suppressing viral replication in the long term,  appear to be safe and largely free of side-
effects.64 As with any antiviral treatment that is taken in the long term, resistance is a concern, but 
tenofovir and entecavir have both so far demonstrated low rates of resistance.65-67 The value of 
these drugs in supporting dentists who are chronic hepatitis B carriers and who wish to return to 
undertaking EPPs in dental practice is described later in this paper. 
HCV 
The transformational progress that has been made recently in the development of new antiviral 
drugs for hepatitis C has been remarkable, but accompanied by controversies regarding the costs of 
the medication which have been reported widely in the media.68, 69 It was not long ago that the only 
treatment available was a combination of pegylated interferon and ribavirin, which was 
administered for 24 or 48 weeks depending on the genotype of the infecting strain.70 Since then, 
understanding of the replication cycle of HCV has improved, allowing the development of direct 
acting antiviral agents (DAAs), which target HCV-encoded proteins that are essential for viral 
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replication.71 In 2011, the first generation protease inhibitors boceprevir and telaprevir were 
licensed for treatment of genotype 1 HCV infections and since then second generation protease 
inhibitors such as sofosbuvir and ledipasvir, with even better efficacy against multiple genotypes, 
fewer drug-drug interactions and with excellent tolerance and safety profiles have emerged.70  The 
proportion of patients receiving the new oral antiviral regimens who achieve a Sustained Viral 
Response (SVR), which equates to a cure, is increasing constantly,71 with data from both clinical trials 
and real world use indicating SVRs in excess of 90%.72, 73 
 
Current management of BBV infected healthcare workers 
The previous two sections of this paper have outlined advances in our understanding of the risks of 
transmission of BBVs from healthcare workers to patients and the mitigation of risk that is possible 
as a result of the massive advances in antiviral drug discovery and approval for clinical use in 
humans. Table 1 summarises the current UK health clearance criteria that must be satisfied before a 
healthcare worker can undertake EPPs. 
In order to appreciate the steps forward that have been made, it is important to recall that until 
2014 no HIV-infected HCWs were permitted to undertake EPPs in the UK. A combination of 
antiretroviral drug treatment and regular occupational / medical health surveillance, including 
measurement of HIV viral load every three months to ensure that it remains < 200 copies/ml, now 
provides an opportunity for those who respond to the medication to return to undertaking EPPs. 
Similarly, antiviral drugs active against HBV now provide an opportunity for chronic HBV carriers who 
satisfy the criteria around e-antigen status, viral load and regular monitoring to return to performing 
EPPs. 
Despite the major advances in HCV anti-viral drug development described earlier, HCWs who are 
HCV RNA-positive are still not permitted to undertake EPPs. However, with arrival of the new oral 
antiviral regimens described above, treatment and cure have become realistic expectations, 
providing a way forward for HCV-infected HCWs who are required to undertake EPPs.   
 
Re-classification of exposure-prone procedures in dentistry 
The risk of transmission of a BBV from an infected HCW to a patient is related ultimately to the 
infectivity of the virus, the viral load of the HCW and the volume of blood that is transferred during 
the incident. Whilst the first two of these criteria can be determined scientifically, this is more 
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difficult for the latter. The approach taken has been to determine the risk of so called 'bleed back’ 
from a HCW into the tissues of a patient should an injury occur during specific medical or dental 
procedures.  
Traditionally this has been managed by determining whether individual clinical interventions satisfy 
the Department of Health definition of an EPP, as defined earlier.2  Those that are defined as EPPs 
are then sub-divided into Categories 1-3 in order of increasing risk of bleed-back. This categorisation, 
which depends largely on expert opinion, is undertaken by groups of experienced clinicians and 
experts for each clinical specialty on behalf of UKAP, which administers the process. 
The first classification of dental procedures was undertaken in 2001, by an expert group which 
included significant input from the British Dental Association. Those involved followed closely the DH 
definition, which includes the phrase ‘These (EPPs) include procedures where the worker’s gloved 
hand may be in contact with sharp instruments, needle tips or sharp tissues (eg spicules of bone or 
teeth) inside a patient’s open body cavity, wound or confined anatomical space, where the hand or 
fingertips may not be completely visible at all times’.2 
By definition, therefore, all intra-oral procedures in the fully or partially dentate mouth were 
classified as exposure-prone. The only dental procedures classified as not being EPPs were: the 
taking of extra-oral radiographs; visual and digital examination of the head and neck; visual and 
digital examination of the edentulous mouth; prescription of antibiotics or other drugs; and 
intravenous sedation. Clearly, the impact on dentists who were excluded from performing EPPs by 
virtue of their BBV status was absolute, since it was impossible to deliver the vast majority of care 
that is normally offered in dental practice and, in effect, impossible to work as a dental practitioner. 
When dental EPPs were reviewed in 2015, knowledge from patient notification exercises since 2001 
provided valuable information on the level of risk to patients from infected dentists. Furthermore, it 
was agreed that injuries to dentists' gloved fingers from patients' teeth and which may result in 
bleed-back are essentially non-existent. For that reason the word 'teeth' was removed from the 
definition of EPPs. The effect was to allow re-categorisation of a significant number of procedures 
from Level 1 EPPs to non-exposure prone activities. Thus, in March 2016, the UKAP specialist dental 
working group published a revised categorisation of EPPs and non-EPPs carried out in general dental 
practice, according to the revised definition: ‘EPPs include procedures where the worker’s gloved 
hands may be in contact with sharp instruments, needle tips or sharp tissues inside a patient’s open 
body cavity, wound or confined anatomical space where the hands or fingertips may not be 
completely visible at all times’. The full details can be accessed at: 
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https://www.gov.uk/government/publications/general-dentistry-exposure-prone-procedure-
categorisation  
This re-categorisation of EPPs in dentistry is summarised in Tables 2 and 3. It will potentially allow 
currently EPP-restricted dentists to perform a wider range of duties as many procedures have now 
been downgraded to non-exposure-prone, including routine oral examination.   
 
Conclusions 
The highly vocational nature of a dental degree and the sparse opportunities for entering sub-
specialities in dentistry, such as dental public health, which do not require the performance of EPPs 
have resulted  in disastrous career-ending situations for a significant number of BBV - infected UK 
dental practitioners in the past. The personal impact on the dentist, his/her family, not to mention 
the practice staff and patients, is devastating.3 For some of those professional colleagues, the 
changes described in this paper have come, sadly, too late but the authors are aware that some have 
now been able to return to work, and in future the change will facilitate a degree of continuity for 
those who choose a career in dentistry. 
The outstanding protection provided by the hepatitis B vaccine, with protection lasting for up to 30 
years,74 was the first important step in reducing the number of HCWs infected with HBV and 
therefore reducing risk of onward transmission to patients. The impact of new antiviral drugs 
represents a second wave of progress in relation to all three BBVs and the future does look 
increasingly bright as even more effective regimens become available, a view reflected by experts in 
the field.75, 76  
Whilst it may be a fanciful, optimistic view, there is every possibility that by the end of the next 
decade, no dental professionals, or any other HCWs for that matter, will be required to cease 
undertaking EPPs long term on the basis of their BBV status – truly an end to being ‘written off’.  
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Table 1 Blood-borne virus status and summary of criteria to be met for exposure prone procedure clearance in 
UK healthcare workers 
Virus Infective status 
 
 
 
 
 
 
Hepatitis B 
HBeAg negative healthcare workers may perform EPPs if they: 
a) have a viral load <300 IU/ml (either from natural suppression or 12 months 
after cessation of antiviral therapy), and 
b) be subject to annual plasma viral load monitoring, and 
c) be under joint supervision of a consultant occupational physician and their 
treating physician,  
HBeAg negative healthcare workers with a pre-treatment viral load of 300 IU/ml – 
30,000 IU/ml may perform EPPs if they: 
a) have a viral load <300 IU/ml whilst on continuous antiviral therapy, and 
b)  be subject to plasma viral load monitoring every three months, and 
c) be under joint supervision of a consultant occupational physician and their 
treating physician,  
 
Hepatitis C  
Must be HCV RNA negative: 
a) as a consequence of natural clearance, or 
b) at 6 months after cessation of antiviral therapy, 
 
 
 
HIV 
Must either: 
a) be on effective combination antiretroviral therapy   (cART), and  
b) have a plasma viral load <200 copies/ml, or 
c) be an elite controller1, and  
d) be subject to plasma viral load monitoring every three months, and 
e) be under joint supervision of a consultant occupational physician and their 
treating physician, and 
f) be registered with the UKAP-OHR 
 
 
 
 
                                                          
1 An elite controller is defined as a person living with HIV  who is not receiving antiretroviral therapy and who 
has maintained their viral load below the limits of assay detection for at least 12 months, based on at least 
three separate viral load measurements 
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Table 2 Dental procedures that are NOT exposure prone 
Procedure 
The taking of intra and extra-oral radiographs 
Visual and digital examination of the head and neck including soft tissue palpation 
Prescription of antibiotics or other drugs 
Intravenous sedation 
Routine oral examination, using mirror and any necessary probes 
All work associated with the construction or replacement of complete or partial dentures  - excluding 
any prior surgical preparation of the hard or soft tissue 
Preventive procedures: oral hygiene instruction, fissure sealing, topical fluoride applications, saliva 
samples 
Taking impressions 
Topical application of, or irrigation with, therapeutic agents 
Suture removal where the hands or fingertips are completely visible at all times 
Supra-gingival or sub-gingival scaling of teeth using an ultrasonic/piezo-sonic scaler 
Polishing of teeth or restorations using a slow-speed hand piece with flexible polishing discs, polishing 
cups or brushes. 
Electro-cautery  
Use of laser when administered external to oral cavity  
Placement of dressings and temporary restorations not requiring tooth preparations 
Orthodontic procedures using removable appliances or aligner techniques e.g. Invisalign®, except 
where interdental stripping with an abrasive strip is required 
Re-implantation of tooth/teeth following trauma (F0830) without bone removal 
Bleaching of teeth, excluding the use of any rotary instrument to provide access required for internal 
bleaching 
Botox or fillers for modification of facial aesthetics administered external to oral cavity  
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Table 3 Categorisation of exposure prone procedures in dentistry 
EPP Category Procedure 
Level 1 
 
(Lowest risk of bleedback) 
Local anaesthetic injections  
Interdental stripping  with a rotary device or abrasive strips for 
orthodontic purposes 
Biopsy of lip (F0620) 
Suture of lip (F0530) 
Polishing of teeth or restorations using finishing burs in high-speed 
handpieces 
Suture removal where the hands or fingertips are not completely 
visible at all times 
Supra-gingival or sub-gingival scaling  of teeth using hand 
instruments 
Level 2 
 
(Intermediate risk of 
bleedback) 
Use of high-speed hand pieces for procedures such as intra-coronal 
restorations and crown and bridge work 
Polishing, finishing or removing overhangs from restoration 
Periodontal surgery 
Root canal therapy 
Root end surgery e.g. apicectomies 
Extractions of teeth including packing and suturing of sockets 
Orthodontic procedures with fixed appliances   
Placement of temporary anchorage devices in the context of 
orthodontic practice 
All other dento-alveolar surgery including:  
 “Surgical removal of impact/buried tooth/teeth (F0910)”;  
 “Surgical removal of complicated buried roots (F0950)”;  
 “Enucleation of cyst of jaw (F1810)”  
Surgical removal of intra-oral soft tissues, including  biopsies 
Frenotomy/frenectomy of tongue (F2620) 
Suturing of  intra-oral soft tissue injuries 
Surgical placement of dental implant 
 
Level 3 
 
(Higher risk of bleedback) 
 
NONE 
 
More extensive oral and maxillo-facial surgery is outwith the present consideration of “general 
dentistry”. Those procedures are considered as general surgery. 
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